Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 16

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 16
---
 Arts degree in Biology from Harvard University, and received his M.D. degree from the University of Pennsylvania School of Medicine, as well as an M.B.A. degree from The Wharton School of the University of Pennsylvania. Dr. de Silva’s experience in the biotechnology industry, and his knowledge of finance, autoimmune therapies and clinical development contributed to our Board’s conclusion that he should serve as a director of our Company.

<div align='center'>8</div>

#### Continuing Members of the Board
Class I Directors (Terms Expire at 2026 Annual Meeting of Stockholders)

The current members of the Board who are Class I Directors are as follows:

| Name                        |     | Age |     | Served as a Director Since |     | Position(s) with Cartesian |
| Michael Singer, M.D., Ph.D. |     |  51 |     |                       2023 |     | Director                   |
| Timothy A. Springer, Ph.D.  |     |  77 |     |                       2016 |     | Director                   |
| Patrick Zenner, M.B.A.      |     |  78 |     |                       2017 |     | Director                   |

The principal occupations and business experience, for at least the past five years, of each Class I Director are as follows:

| MICHAEL SINGER, M.D., PH.D. |     | Age | 51 |

Michael Singer, M.D., Ph.D. co-founded and served as Chief Scientific Officer, later Chief Strategy Officer, and Chairman of the Board of the private company then known as Cartesian Therapeutics, Inc. (“Old Cartesian”) from 2016 until its acquisition by the Company in 2023. Prior to Old Cartesian, Dr. Singer co-founded and served as Chief Scientific Officer of Topokine Therapeutics, Inc. from 2012 to 2016. Prior to Topokine, he served as a medical director at Novartis from 2009 to 2012 and co-founded and served as Chief Scientific Officer of HealthHonors Corporation from 2006 to 2009. He has served as a member of the board of Bioporto A/S since 2019, Pykus Therapeutics since 2019, and Anodyne Nanotech since 2020. Dr. Singer received his B.S. in biology, M.Phil and Ph.D. in neuroscience, and M.D. from Yale University and completed internship and residency at Harvard. He is a registered U.S.